Abivax resumes trading of its shares on Euronext Paris

Abivax, a clinical-stage biotechnology company, announces the resumption of trading of its ordinary shares on Euronext Paris. Trading was suspended this morning at 9:00 a.m. CEST. This interruption was in response to a request from the company, in connection with its public offering in the United States of its American Depositary Shares.

This initiative aims to confirm the allocations to investors and announce the final terms of the offering. Trading is scheduled to resume at 3:30 p.m. CEST. Abivax focuses on treatments for chronic inflammatory diseases, harnessing the body's natural regulatory mechanisms.

This decision is strategic in the development and stabilization of the immune response, particularly for patients with ulcerative colitis.